-
Product Name
RBBP9 antibody
- Documents
-
Description
RBBP9 Mouse Monoclonal antibody. Positive WB detected in A549 cell. Positive IHC detected in human pancreas tissue, human pancreas cancer tissue. Observed molecular weight by Western-blot: 22 kDa
-
Tested applications
ELISA, WB, IHC
-
Species reactivity
Human; other species not tested.
-
Isotype
Mouse IgG2b
-
Preparation
This antibody was obtained by immunization of RBBP9 recombinant protein (Accession Number: NM_006606). Purification method: Protein A purified.
-
Clonality
Monoclonal
-
Formulation
PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
-
Storage instructions
Store at -20℃. DO NOT ALIQUOT
-
Applications
Recommended Dilution:
WB: 1:200-1:2000
IHC: 1:20-1:200
-
Validations
A549 cells were subjected to SDS PAGE followed by western blot with Catalog No:107499(RBBP9 antibody) at dilution of 1:500
Immunohistochemical of paraffin-embedded human pancreas using Catalog No:107499(RBBP9 antibody) at dilution of 1:50 (under 10x lens)
Immunohistochemical of paraffin-embedded human pancreas using Catalog No:107499(RBBP9 antibody) at dilution of 1:50 (under 40x lens)
-
Background
RBBP9, also named as BOG, RBBP10, RBBP-9, RBBP-10 and Protein BOG, belongs to the RBBP9 family. It may play a role in the transformation process due to its capacity to confer resistance to the growth-inhibitory effects of TGF-β1 through interaction with retinoblastoma and the subsequent displacement of E2F-1. RBBP9 is a tumor-associated serine hydrolase activity required for pancreatic neoplasia. It mediates suppression of TGF-β signaling is required for E-cadherin expression as loss of the serine hydrolase activity leads to a reduction in E-cadherin levels and a concomitant decrease in the integrity of tumor cell–cell junctions..RBBP9 protein levels were equivalent in paired primary tumor and nonneoplastic specimens(PMID:20080647)
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"